ANGLE plc, a world-leading liquid biopsy company, will be releasing its interim results for the six months ended 31 October 2017 on Wednesday 31 January 2018.
| GUILDFORD, SURREY -- (Marketwired) -- Jan 10, 2018 -- ANGLE plc (
For Immediate Release 10 January 2018 ANGLE plc Notification of Interim Results and Webcast ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its interim results for the six months ended 31 October 2017 on Wednesday 31 January 2018. A meeting for analysts will be held at 10.30am on 31 January 2018 at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London EC1A 4HD. A live webcast of the analyst meeting will also be available on ANGLE’s Investor Centre page, http://www.angleplc.com/investor-information/investor-centre/. Please log on to the web address approximately 5 minutes before 10.30 am on the day of the results. A recording of the webcast will also be made available on ANGLE’s website, www.ANGLEplc.com, following the results meeting. For further information:
ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director finnCap Ltd (NOMAD and Joint Broker) +44 (0) 20 7220 0500 Corporate Finance - Adrian Hargrave, Simon Hicks, Kate Bannatyne Corporate Broking - Alice Lane, Nikita Jain WG Partners (Joint Broker) +44 (0) 203 705 9330 Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee FTI Consulting Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000 Kimberly Ha (US) +1 212 850 5612 For Frequently Used Terms, please see the Company’s website on http://www.angleplc.com/the-parsortix-system/glossary/ Notes for editors About ANGLE plc www.angleplc.com ANGLE’s cell separation technology is called the Parsortix™ system and it enables a liquid biopsy (simple blood test) to be used to provide the cells of interest. Parsortix is the subject of granted patents in Europe, the United States, Canada, India, China, Japan and Australia and three extensive families of patents are being progressed worldwide. The system is based on a microfluidic device that captures live cells based on a combination of their size and compressibility. The Parsortix system has a CE Mark for Europe and FDA clearance is in process for the United States. ANGLE’s analysis technology for proteins and nucleic acids of all types is based on a patented flow through array technology. It provides for highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. These technologies can be combined to provide fully automated, sample to answer results in both centralized laboratory and point of use cartridge formats. It is ideal for measuring gene expression and other markers directly from Parsortix harvests. ANGLE has established formal collaborations with world-class cancer centres. These Key Opinion Leaders are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. Details are available here http://www.angleplc.com/the-company/collaborators/ The analysis of the cells that can be harvested from patient blood with ANGLE’s Parsortix system has the potential to help deliver personalised cancer care offering profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer. The global increase in cancer to a 1 in 3 lifetime incidence is set to drive a multi-billion dollar clinical market. The Parsortix system is designed to be compatible with existing major medtech analytical platforms and to act as a companion diagnostic for major pharma in helping to identify patients that will benefit from a particular drug and then monitoring the drug’s effectiveness. As well as cancer, the Parsortix technology has the potential for deployment with several other important cell types in the future. ANGLE biomarker analysis platforms are adaptable to measure protein and nucleic acid biomarkers across the full spectrum of disease applications. ANGLE stock trades on the AIM market of the London Stock Exchange under the ticker symbol AGL and in New York on the OTC-QX under the ticker symbol ANPCY. For further information please visit: www.angleplc.com This information is provided by RNS
Contacts: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com
|
